Neural Therapeutics (XCNQ:NURL) Days Payable: 0.00 (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Days Payable?

Neural Therapeutics XCNQ:NURL Days Payable is 0.00 as of Jan. 2026. The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, Neural Therapeutics ranks worse than 142450% on this metric.

Neural Therapeutics's average Accounts Payable for the three months ended in Jan. 2026 was C$0.04 Mil. Neural Therapeutics's Cost of Goods Sold for the three months ended in Jan. 2026 was C$0.00 Mil.

The historical rank and industry rank for Neural Therapeutics's Days Payable or its related term are showing as below:

XCNQ:NURL's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Neural Therapeutics's Days Payable stayed the same from Jan. 2025 (0.00) to Jan. 2026 (0.00). stayed the same

Neural Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Days Payable Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Days Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XCNQ:NURL vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Neural Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neural Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neural Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Neural Therapeutics's Days Payable falls into.


Neural Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Neural Therapeutics's Days Payable for the fiscal year that ended in Jul. 2025 is calculated as

Days Payable (A: Jul. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jul. 2024 ) + Accounts Payable (A: Jul. 2025 )) / count ) / Cost of Goods Sold (A: Jul. 2025 )*Days in Period
=( (0.087 + 0.03) / 2 ) / 0*365
=0.0585 / 0*365
=N/A

Neural Therapeutics's Days Payable for the quarter that ended in Jan. 2026 is calculated as:

Days Payable (Q: Jan. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Oct. 2025 ) + Accounts Payable (Q: Jan. 2026 )) / count ) / Cost of Goods Sold (Q: Jan. 2026 )*Days in Period
=( (0.033 + 0.055) / 2 ) / 0*365 / 4
=0.044 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Neural Therapeutics (XCNQ:NURL) has a Days Payable of 0.00 as of Jan. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #999999 out of 702 companies in the Biotechnology industry.
Is Neural Therapeutics' Days Payable too high?
Neural Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Neural Therapeutics ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neural Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #999999 out of 702 companies for Days Payable. This places Neural Therapeutics in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neural Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neural Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (XCNQ:NURL) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neural Therapeutics (XCNQ:NURL), the current Days Payable is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:Germany
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.